

Supplemental Table 12. Clinical characteristics of melanoma patients treated with anti-PD-1 with or without anti-CTLA-4

Clinical Characteristic	Number (out of 60 total patients)
Age	
Median	65.5, range 21-91
Sex	
Female	26 (43%)
Race	
White	55 (91%)
Treatment regimen	
Anti-PD-1 monotherapy	35 (58%)
Tumor mutation	
BRAF	19 (32%)
NRAS	9 (15%)
c-kit	3 (5%)
WT for BRAF, NRAS and c-Kit	29 (48%)
Baseline serum lactate dehydrogenase	
Elevated	10 (16%)
Type of melanoma	
Cutaneous	49 (82%)
Mucosal	7 (11%)
Unknown	4 (7%)
M Stage	
M1a	14 (23%)
M1b	22 (37%)
M1c	14 (23%)
M1d	7 (11%)
Unknown	4 (6%)
Response to immunotherapy	
Complete Response (CR)	13 (22%)
Partial Response (PR)	16 (27%)
Stable Disease (SD)	9 (15%)
Progressive Disease (PD)	22 (37%)

Supplemental Table 13. Multivariable analysis of tumor RNLS levels and association with overall survival

Variable	Hazard ratio (95%CI)	P value
RNLS (High/Low)	2.77 (1.34-5.92)	0.0054
Age (older/younger>)	1.68(0.82-3.5)	0.14
Gender (female/male)	1.05(0.51-2.1)	0.87
Treatment (mono/dual therapy)	1.77(0.88-3.66)	0.1
LDH (elevated/normal)	5.29(1.98-13.98)	0.0012
M stage (M1a+M1b/M1c+M1d)	0.93(0.43-2.07)	1.06
BRAF (mutation/(WT)	0.64 (0.26-1.42)	0.28